<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82446">
  <stage>Registered</stage>
  <submitdate>27/11/2007</submitdate>
  <approvaldate>28/11/2007</approvaldate>
  <actrnumber>ACTRN12607000613404</actrnumber>
  <trial_identification>
    <studytitle>An Assessment of the Effects of a Nutritional Supplement Program on Healthy Aging</studytitle>
    <scientifictitle>In patients with osteoarthritis of the knee does Ambrotose powder, Ambrotose AO, Phytomatrix and Plus 1, increase the quality of life and fatigue level?
</scientifictitle>
    <utrn />
    <trialacronym>None</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Quality of life and fatigue in osteoarthritis of the knee</healthcondition>
    <healthcondition>Increases in quality of life and fatigue in individuals with osteoarthritis of the knee</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ambrotose powder 1 teaspoon twice a day with food for 8 weeks
Ambrotose AO, 2 capsules twice a day with food for 8 weeks
Phytomatrix 1 capsule twice a day with food for 8 weeks
Plus 1 capsule twice a day with food for 8 weeks</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Brief Fatigue Inventory.</outcome>
      <timepoint>Screening, Baseline (week 1), week 4, week 8 (end of study)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>COAT (Comprehensive Osteoarthritis Test) - This instrument consists of four items measured on 100mm visual analogue scale (VAS) response scales: joint pain, stiffness, difficulties with physical activities, and overall symptoms.</outcome>
      <timepoint>Screening, Baseline (week 1), week 4, week 8 (end of study)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prospective Retrospective Memory Questionnaire</outcome>
      <timepoint>Screening, Baseline (week 1), week 4, week 8 (end of study)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life Index Arthritis Version ? III</outcome>
      <timepoint>Screening, Baseline (week 1), week 4, week 8 (end of study)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Status Questionnaire 2.0</outcome>
      <timepoint>Screening, Baseline (week 1), week 4, week 8 (end of study)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Mood States</outcome>
      <timepoint>Screening, Baseline (week 1), week 4, week 8 (end of study)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Females and males, aged between 18 and 85 years
X-ray and clinical evidence of osteoarthritis of the knees
In good general health
Adequate venous access
Female participants of childbearing age who agree to continue using birth control measures for the duration of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>A history of trauma associated with the affected joint
Rheumatoid or other inflammatory joint conditions
Gout
Individuals with thyroid disorder
Individuals with diabetes
Individuals taking antidepressants
Individuals taking Warfarin of other anti-coagulant medication
Individuals who are lactose intolerant
Participants with a VAS score above 7 at baseline.
Participants who have just commenced on a treatment regimen for arthritis 
Use of corticosteroids (intra-articular or systematic) within 4 weeks prior to baseline and throughout the study
Liver function tests greater than 3 times the upper limit of normal at baseline
History of alcohol or substance abuse
History of allergy to iodine or shell fish
Female participants who are lactating, pregnant or planning to become pregnant
Participants who have participated in another clinical trial in the last 30 days
Participants unwilling to comply with the study protocol
Any other condition, which in the opinion of the investigators could compromise the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2480</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Mannatech Australia Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Level 3 69 Christie Street  St Leonards NSW 2064</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Mannatech Australia Pty Ltd</fundingname>
      <fundingaddress>Level 3 69 Christie Street  St Leonards NSW 2064</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Mannatech Australia Pty Ltd</fundingname>
      <fundingaddress>Level 3 69 Christie Street  St Leonards NSW 2064</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Mannatech Australia Pty Ltd</fundingname>
      <fundingaddress>Level 3 69 Christie Street  St Leonards NSW 2064</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>NatMed-Research Southern Cross University</othercollaboratorname>
      <othercollaboratoraddress>Southern Cross University Military Road Lismore NSW 2480</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine the efficacy and safety of a Mannatech product in improving quality of life and reducing fatigue in participants with diagnosed osteoarthritis of the knee.  Participants will take 4 Mannatech preperations twice a day with food for 8 weeks, they will attend a clinic at baseline, week 4 and week 8.  At these times they will complete the study questionnaires.  Blood wil be taken at baseline and week 8 to determine safety parameters.</summary>
    <trialwebsite>None</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Cross University Human Research Ethics Committee</ethicname>
      <ethicaddress>Southern Cross University Military Road Lismore NSW 2480</ethicaddress>
      <ethicapprovaldate>5/10/2007</ethicapprovaldate>
      <hrec>ECN-07-128</hrec>
      <ethicsubmitdate>17/09/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Joan O'Connor</name>
      <address>NatMed-Research
Department fo Natural and Complementary Medicine, School of Health and Human Sciences, Southern Cross Universtiy.PO Box 157 Lismore NSW 2480</address>
      <phone>02 66 20 3649</phone>
      <fax>01 66 20 3307</fax>
      <email>joan.oconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Joan O'Connor</name>
      <address>NatMed-Research
Department fo Natural and Complementary Medicine, School of Health and Human Sciences, Southern Cross Universtiy.PO Box 157 Lismore NSW 2480</address>
      <phone>02 66 20 3649</phone>
      <fax>01 66 20 3307</fax>
      <email>joan.oconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Joan O'Connor</name>
      <address>NatMed-Research
Department fo Natural and Complementary Medicine, School of Health and Human Sciences, Southern Cross Universtiy.PO Box 157 Lismore NSW 2480</address>
      <phone>02 66 20 3649</phone>
      <fax>01 66 20 3307</fax>
      <email>joan.oconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>